Analysis reveals Mycoplasma pneumoniae causes pediatric pneumonia, suggesting early recognition and alternative therapy may enhance outcomes.
During the 2024-2025 outbreak, M. pneumoniae caused predominantly paediatric CAP but occasionally severe disease requiring intensive care. The frequent need to switch from macrolides suggests emerging resistance. Early recognition and use of alternative agents such as doxycycline or fluoroquinolones may improve outcomes.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: